{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T04:58:26Z","timestamp":1784177906830,"version":"3.55.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Recent studies have demonstrated a distressing lack of diversity in urology clinical trials. Diversity is important to ensure that trial outcomes accurately represent the gamut of patients with a condition. We aimed to assess the current literature landscape of ethnic and racial diversity on clinical trials for Peyronie\u2019s disease (PD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Investigate the representation of different racial and ethnic groups in PD clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In September 2024, a systematic review of Peyronie\u2019s disease clinical trials in the published English literature was performed using the Ovid, Embase, and Medline\/PubMed databases. Articles were included if they were in English, relevant to Peyronie\u2019s disease, and specified clinical trial in the title or abstract. Articles were excluded if they included patients with congenital penile curvature, pooled analyses, abstracts with incomplete information, and\/or ongoing incomplete clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The initial search yielded 494 studies. After screening, and full-text review, 75 articles met the inclusion criteria. Of the 75 articles included in this systematic review, only 10 (13.3%) reported participant race and ethnicity with a pooled population totaling 1948 men. All 10 studies reported enrollment of Caucasian men, with Caucasian men making up 95.6% of the enrolled population. Enrollment of Black men was reported in 6 of the 10 studies and constituted 4% of included patients. Enrollment of Asian men was reported in 2 (2.6%) studies and comprised 0.1% of included patients. Enrollment of American Indian\/Native American men was reported in only 1 (1.4%) study and comprised 0.05% of patients. Hispanic ethnicity was the only ethnicity reported and was available in 5 (8.1%) studies with 3.8% of men reported as Hispanic.<\/jats:p>\n                  <jats:p>Five of the 10 studies that reported race enrolled patients exclusively from the United States.<\/jats:p>\n                  <jats:p>The 5 US-based studies showed a significant disparity in representation compared to the 2020 US Census (P\u2009&amp;lt;\u2009.001). Caucasian men were overrepresented, while all other racial and ethnic groups were underrepresented.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is an over-representation of Caucasian men and an underrepresentation of other races, along with a lack of representation of racial and ethnic minorities with PD. This may lead to clinical trial outcomes being non-generalizable. Further studies with diverse populations are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdaf134","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T13:13:49Z","timestamp":1751030029000},"page":"1455-1464","source":"Crossref","is-referenced-by-count":1,"title":["Diversity matters in Peyronie\u2019s disease clinical trials\u2014a systematic review"],"prefix":"10.1093","volume":"22","author":[{"given":"Marcelo","family":"Mass Lindenbaum","sequence":"first","affiliation":[{"name":"Men\u2019s Health Section, Glickman Urological Institute, Cleveland Clinic Foundation , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardita M","family":"Ljubetic","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Section, Glickman Urological Institute, Cleveland Clinic Foundation , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Leelani","sequence":"additional","affiliation":[{"name":"Department of Urology, Maimonides Medical Center , Brooklyn, NY 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajit","family":"Khooblall","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Section, Glickman Urological Institute, Cleveland Clinic Foundation , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raevti","family":"Bole","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Section, Glickman Urological Institute, Cleveland Clinic Foundation , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D","family":"Lundy","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Section, Glickman Urological Institute, Cleveland Clinic Foundation , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petar","family":"Bajic","sequence":"additional","affiliation":[{"name":"Men\u2019s Health Section, Glickman Urological Institute, Cleveland Clinic Foundation , Cleveland, OH 44195 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"2","key":"2025080406264453100_ref1","doi-asserted-by":"publisher","first-page":"e00195","DOI":"10.1002\/edm2.195","article-title":"Fibroproliferative disorders and diabetes: understanding the pathophysiologic relationship between Peyronie\u2019s disease, Dupuytren disease and diabetes","volume":"4","author":"Gelbard","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"2025080406264453100_ref2","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/sxmrev\/qeae006","article-title":"Research advances in Peyronie\u2019s disease: a comprehensive review on genomics, pathways, phenotypic manifestation, and therapeutic targets","volume":"12","author":"Chi","year":"2024","journal-title":"Sex Med Rev"},{"key":"2025080406264453100_ref3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/RRU.S65620","article-title":"A review of the epidemiology and treatment of Peyronie\u2019s disease","volume":"8","author":"Ostrowski","year":"2016","journal-title":"Res Rep Urol"},{"issue":"10","key":"2025080406264453100_ref4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.amjmed.2021.06.015","article-title":"Peyronie disease as a marker of inflammation-is there hope on the horizon?","volume":"134","author":"Swislocki","year":"2021","journal-title":"Am J Med"},{"issue":"2","key":"2025080406264453100_ref5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.juro.2013.01.090","article-title":"Bother and distress associated with Peyronie\u2019s disease: validation of the Peyronie\u2019s disease questionnaire","volume":"190","author":"Hellstrom","year":"2013","journal-title":"J Urol"},{"key":"2025080406264453100_ref6","doi-asserted-by":"publisher","first-page":"100986","DOI":"10.1016\/j.conctc.2022.100986","article-title":"An evaluation of race-based representation among men participating in clinical trials for prostate cancer and erectile dysfunction","volume":"29","author":"Saltzman","year":"2022","journal-title":"Contemp Clin Trials Commun"},{"issue":"22","key":"2025080406264453100_ref7","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"issue":"1","key":"2025080406264453100_ref8","doi-asserted-by":"publisher","first-page":"pkab093","DOI":"10.1093\/jncics\/pkab093","article-title":"Racial disparities in access to prostate cancer clinical trials: a county-level analysis","volume":"6","author":"Wang","year":"2022","journal-title":"JNCI Cancer Spectr"},{"issue":"5","key":"2025080406264453100_ref9","doi-asserted-by":"publisher","first-page":"195.e13","DOI":"10.1016\/j.urolonc.2021.11.015","article-title":"Race, ethnicity, and gender reporting in north American clinical trials for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Fletcher","year":"2022","journal-title":"Urol Oncol"},{"issue":"8","key":"2025080406264453100_ref10","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10552-022-01593-8","article-title":"Race reporting and disparities regarding clinical trials in bladder cancer: a systematic review","volume":"33","author":"Freudenburg","year":"2022","journal-title":"Cancer Causes Control"},{"issue":"Suppl 7","key":"2025080406264453100_ref11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/cncr.28575","article-title":"Twenty years post-NIH revitalization act: enhancing minority participation in clinical trials (EMPaCT): laying the groundwork for improving minority clinical trial accrual: renewing the case for enhancing minority participation in cancer clinical trials","volume":"120","author":"Chen","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"2025080406264453100_ref12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.7326\/0003-4819-125-8-199610150-00008","article-title":"The medicalization of race: scientific legitimization of a flawed social construct","volume":"125","author":"Witzig","year":"1996","journal-title":"Ann Intern Med"},{"issue":"1","key":"2025080406264453100_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40246-014-0023-x","article-title":"Self-reported race\/ethnicity in the age of genomic research: its potential impact on understanding health disparities","volume":"9","author":"Mersha","year":"2015","journal-title":"Hum Genomics"},{"key":"2025080406264453100_ref14","volume-title":"NOT-OD-15-015: Notice of Revised NIH Definition of Clinical Trial"},{"issue":"1","key":"2025080406264453100_ref15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0022-5347(17)35998-0","article-title":"Collagenase versus placebo in the treatment of Peyronie\u2019s disease: a double-blind study","volume":"149","author":"Gelbard","year":"1993","journal-title":"J Urol"},{"issue":"4","key":"2025080406264453100_ref16","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00295900","article-title":"Induratio penis plastica: effectivity of low-dose radiotherapy at different clinical stages","volume":"24","author":"Koren","year":"1996","journal-title":"Urol Res"},{"issue":"4","key":"2025080406264453100_ref17","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie\u2019s disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"issue":"4","key":"2025080406264453100_ref18","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1002\/j.1939-4640.1999.tb02539.x","article-title":"A pilot study demonstrating clinical benefit from intralesional interferon alpha 2B in the treatment of Peyronie\u2019s disease","volume":"20","author":"Ahuja","year":"1999","journal-title":"J Androl"},{"issue":"6","key":"2025080406264453100_ref19","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/S0022-5347(05)68087-1","article-title":"Tamoxifen versus placebo in the treatment of Peyronie\u2019s disease","volume":"162","author":"Teloken","year":"1999","journal-title":"J Urol"},{"issue":"5","key":"2025080406264453100_ref20","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S0022-5347(05)67639-2","article-title":"Application of pericardial graft in the surgical management of Peyronie\u2019s disease","volume":"163","author":"Hellstrom","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"2025080406264453100_ref21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/j.1939-4640.2000.tb03279.x","article-title":"Transdermal electromotive multi-drug administration for Peyronie\u2019s disease: preliminary results","volume":"21","author":"Montorsi","year":"2000","journal-title":"J Androl"},{"issue":"1","key":"2025080406264453100_ref22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0022-5347(05)67981-5","article-title":"Iontophoresis for treatment of Peyronie\u2019s disease","volume":"163","author":"Riedl","year":"2000","journal-title":"J Urol"},{"issue":"1","key":"2025080406264453100_ref23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1046\/j.1464-410x.2001.02241.x","article-title":"Acetyl-L-carnitine vs tamoxifen in the oral therapy of Peyronie\u2019s disease: a preliminary report","volume":"88","author":"Biagiotti","year":"2001","journal-title":"BJU Int"},{"issue":"7","key":"2025080406264453100_ref24","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1046\/j.1464-410x.2001.02139.x","article-title":"Treatment of Peyronie\u2019s disease with local interferon-alpha 2b","volume":"87","author":"Brake","year":"2001","journal-title":"BJU Int"},{"issue":"9","key":"2025080406264453100_ref25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1046\/j.1464-410X.2002.02738.x","article-title":"Oral propionyl-l-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie\u2019s disease","volume":"89","author":"Cavallini","year":"2002","journal-title":"BJU Int"},{"issue":"4","key":"2025080406264453100_ref26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0302-2838(02)00024-6","article-title":"Collagen fleece for defect coverage following plaque excision in patients with Peyronie\u2019s disease","volume":"41","author":"Lahme","year":"2002","journal-title":"Eur Urol"},{"issue":"6","key":"2025080406264453100_ref27","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1046\/j.1464-410X.2003.04134.x","article-title":"Combined treatment with vitamin E and colchicine in the early stages of Peyronie\u2019s disease","volume":"91","author":"Prieto Castro","year":"2003","journal-title":"BJU Int"},{"issue":"3","key":"2025080406264453100_ref28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1590\/S1677-55382004000300004","article-title":"An alternative non-invasive treatment for Peyronie\u2019s disease","volume":"30","author":"Claro","year":"2004","journal-title":"Int Braz J Urol"},{"issue":"4","key":"2025080406264453100_ref29","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1097\/01.ju.0000116450.82816.2c","article-title":"A prospective, randomized study using transdermal electromotive administration of verapamil and dexamethasone for Peyronie\u2019s disease","volume":"171","author":"Di Stasi","year":"2004","journal-title":"J Urol"},{"issue":"3","key":"2025080406264453100_ref30","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/sj.ijir.3901185","article-title":"Therapeutic effects of colchicine in the management of Peyronie\u2019s disease: a randomized double-blind, placebo-controlled study","volume":"16","author":"Safarinejad","year":"2004","journal-title":"Int J Impot Res"},{"issue":"5","key":"2025080406264453100_ref31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1743-6109.2005.00110.x","article-title":"The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie\u2019s disease","volume":"2","author":"Kendirci","year":"2005","journal-title":"J Sex Med"},{"issue":"4","key":"2025080406264453100_ref32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/02656730500133892","article-title":"Role of hyperthermia in the treatment of Peyronie\u2019s disease: a preliminary study","volume":"21","author":"Perugia","year":"2005","journal-title":"Int J Hyperth"},{"issue":"4","key":"2025080406264453100_ref33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.eururo.2005.04.011","article-title":"Liposomal recombinant human superoxide dismutase for the treatment of Peyronie\u2019s disease: a randomized placebo-controlled double-blind prospective clinical study","volume":"48","author":"Riedl","year":"2005","journal-title":"Eur Urol"},{"key":"2025080406264453100_ref34","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2004.12.022","article-title":"& Peyronie\u2019s disease study Group of Andrological Group of German urologists. Potassium paraaminobenzoate (POTABA) in the treatment of Peyronie\u2019s disease: a prospective, placebo-controlled, randomized study","volume":"47","author":"Weidner","year":"2005","journal-title":"Eur Urol"},{"issue":"1","key":"2025080406264453100_ref35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S0022-5347(06)00517-9","article-title":"Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie\u2019s disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J Urol"},{"issue":"5","key":"2025080406264453100_ref36","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.urology.2005.11.005","article-title":"Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie\u2019s disease: a randomized and prospective study","volume":"67","author":"Inal","year":"2006","journal-title":"Urology"},{"issue":"6","key":"2025080406264453100_ref37","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","article-title":"Intralesional verapamil prevents the progression of Peyronie\u2019s disease","volume":"69","author":"Bennett","year":"2007","journal-title":"Urology"},{"issue":"5","key":"2025080406264453100_ref38","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.urology.2007.01.080","article-title":"Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie\u2019s disease","volume":"69","author":"Cavallini","year":"2007","journal-title":"Urology"},{"issue":"2","key":"2025080406264453100_ref39","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/j.1743-6109.2006.00417.x","article-title":"Topical verapamil HCl, topical Trifluoperazine, and topical magnesium Sulfate for the treatment of Peyronie\u2019s disease\u2014 a placebo-controlled pilot study","volume":"4","author":"Fitch","year":"2007","journal-title":"J Sex Med"},{"issue":"3","key":"2025080406264453100_ref40","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.juro.2006.10.065","article-title":"verapamil versus saline in electromotive drug administration for Peyronie\u2019s disease: a double-blind, placebo controlled trial","volume":"177","author":"Greenfield","year":"2007","journal-title":"J Urol"},{"issue":"4","key":"2025080406264453100_ref41","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1016\/j.juro.2007.05.162","article-title":"Comparison of vitamin E and propionyl-L-carnitine, separately or in combination, in patients with early chronic Peyronie\u2019s disease: a double-blind, placebo controlled, randomized study","volume":"178","author":"Safarinejad","year":"2007","journal-title":"J Urol"},{"issue":"1","key":"2025080406264453100_ref42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1743-6109.2007.00651.x","article-title":"The use of intralesional clostridial collagenase injection therapy for Peyronie\u2019s disease: a prospective, single-center, non-placebo-controlled study","volume":"5","author":"Jordan","year":"2008","journal-title":"J Sex Med"},{"issue":"2","key":"2025080406264453100_ref43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.eururo.2009.05.012","article-title":"A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie\u2019s disease","volume":"56","author":"Palmieri","year":"2009","journal-title":"Eur Urol"},{"issue":"3","key":"2025080406264453100_ref44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie\u2019s disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"issue":"1","key":"2025080406264453100_ref45","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11255-008-9408-x","article-title":"The effectiveness of transdermal electromotive administration with verapamil and dexamethasone in the treatment of Peyronie\u2019s disease","volume":"41","author":"Tuygun","year":"2009","journal-title":"Int Urol Nephrol"},{"issue":"9","key":"2025080406264453100_ref46","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1111\/j.1464-410X.2010.09331.x","article-title":"Limited shock wave therapy vs sham treatment in men with Peyronie\u2019s disease: results of a prospective randomized controlled double-blind trial","volume":"106","author":"Chitale","year":"2010","journal-title":"BJU Int"},{"issue":"4","key":"2025080406264453100_ref47","first-page":"291","article-title":"Evaluation of intralesional injection of verapamil in treatment of Peyronie\u2019s disease","volume":"60","author":"Heidari","year":"2010","journal-title":"J Pak Med Assoc"},{"issue":"5","key":"2025080406264453100_ref48","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/ijir.2010.20","article-title":"Safety and efficacy of coenzyme Q10 supplementation in early chronic Peyronie\u2019s disease: a double-blind, placebo-controlled randomized study","volume":"22","author":"Safarinejad","year":"2010","journal-title":"Int J Impot Res"},{"issue":"11","key":"2025080406264453100_ref49","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1111\/j.1743-6109.2010.01924.x","article-title":"Nicardipine vs. saline injection as treatment for Peyronie\u2019s disease: a prospective, randomized, single-blind trial","volume":"7","author":"Soh","year":"2010","journal-title":"J Sex Med"},{"issue":"6","key":"2025080406264453100_ref50","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"issue":"1","key":"2025080406264453100_ref51","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/j.2047-2927.2012.00018.x","article-title":"Comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for Peyronie\u2019s disease","volume":"1","author":"Mehrsai","year":"2013","journal-title":"Andrology"},{"issue":"2","key":"2025080406264453100_ref52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2605.2011.01226.x","article-title":"Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie\u2019s disease and erectile dysfunction: results from a prospective randomized trial","volume":"35","author":"Palmieri","year":"2012","journal-title":"Int J Androl"},{"issue":"1","key":"2025080406264453100_ref53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1464-410X.2011.10733.x","article-title":"Safety and tolerability of local treatment with iloprost, a prostacyclin analogue, in patients with Peyronie\u2019s disease: a phase I study","volume":"110","author":"Pavone","year":"2012","journal-title":"BJU Int"},{"issue":"8","key":"2025080406264453100_ref54","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/and.12178","article-title":"Combination of intralesional verapamil and oral antioxidants for Peyronie\u2019s disease: a prospective, randomised controlled study","volume":"46","author":"Favilla","year":"2014","journal-title":"Andrologia"},{"issue":"11","key":"2025080406264453100_ref55","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1111\/jsm.12312","article-title":"Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie\u2019s disease","volume":"10","author":"Gelbard","year":"2013","journal-title":"J Sex Med"},{"issue":"11","key":"2025080406264453100_ref56","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1111\/jsm.12275","article-title":"Extracorporeal shock wave therapy in Peyronie\u2019s disease: results of a placebo-controlled, prospective, randomized, single-blind study","volume":"10","author":"Hatzichristodoulou","year":"2013","journal-title":"J Sex Med"},{"issue":"1","key":"2025080406264453100_ref57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.2047-2927.2012.00007.x","article-title":"Efficacy of vitamin E in the conservative treatment of Peyronie\u2019s disease: legend or reality? A controlled study of 70 cases","volume":"1","author":"Paulis","year":"2013","journal-title":"Andrology"},{"issue":"7","key":"2025080406264453100_ref58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5539\/gjhs.v6n7p23","article-title":"Evaluation of verapamil efficacy in Peyronie\u2019s disease comparing with pentoxifylline","volume":"6","author":"Alizadeh","year":"2014","journal-title":"Global J Health Sci"},{"issue":"2","key":"2025080406264453100_ref59","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/jsm.12400","article-title":"Acute phase Peyronie\u2019s disease management with traction device: a non-randomized prospective controlled trial with ultrasound correlation","volume":"11","author":"Mart\u00ednez-Salamanca","year":"2014","journal-title":"J Sex Med"},{"issue":"3","key":"2025080406264453100_ref60","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11845-013-1036-5","article-title":"Effects of sildenafil treatment on patients with Peyronie\u2019s disease and erectile dysfunction","volume":"183","author":"Ozturk","year":"2014","journal-title":"Ir J Med Sci"},{"issue":"3","key":"2025080406264453100_ref61","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4103\/0974-7796.152048","article-title":"Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie\u2019s disease","volume":"7","author":"Dell\u2019Atti","year":"2015","journal-title":"Urol Ann"},{"issue":"1","key":"2025080406264453100_ref62","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/jsm.12731","article-title":"Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie\u2019s disease: a phase 3 open-label study","volume":"12","author":"Levine","year":"2015","journal-title":"J Sex Med"},{"issue":"10","key":"2025080406264453100_ref63","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.7556\/jaoa.2015.124","article-title":"Effects of stem cell treatment in human patients with Peyronie disease","volume":"115","author":"Levy","year":"2015","journal-title":"J Am Osteopath Assoc"},{"issue":"5","key":"2025080406264453100_ref64","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1590\/S1677-5538.IBJU.2015.0598","article-title":"A prospective, randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie\u2019s disease: a pilot study","volume":"42","author":"Toscano","year":"2016","journal-title":"Int Braz J Urol"},{"issue":"2","key":"2025080406264453100_ref65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/ijir.2015.22","article-title":"Topical treatment for acute phase Peyronie\u2019s disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study","volume":"28","author":"Twidwell","year":"2016","journal-title":"Int J Impot Res"},{"issue":"4 Part 1","key":"2025080406264453100_ref66","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.juro.2015.10.065","article-title":"Restoration of penile function and patient satisfaction with Intralesional collagenase clostridium Histolyticum injection for Peyronie\u2019s disease","volume":"195","author":"Ziegelmann","year":"2016","journal-title":"J Urol"},{"issue":"4","key":"2025080406264453100_ref67","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/andr.12368","article-title":"Evaluation of intralesional injection of hyaluronic acid compared with verapamil in Peyronie\u2019s disease: preliminary results from a prospective, double-blinded, randomized study","volume":"5","author":"Favilla","year":"2017","journal-title":"Andrology"},{"issue":"2","key":"2025080406264453100_ref68","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1016\/j.esxm.2017.02.001","article-title":"Changes in the effects of Peyronie\u2019s disease after treatment with collagenase clostridium histolyticum: male patients and their female partners","volume":"5","author":"Goldstein","year":"2017","journal-title":"Sex Med"},{"issue":"1","key":"2025080406264453100_ref69","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000467396","article-title":"Does transfer capacitive resistive energy has a therapeutic effect on Peyronie\u2019s disease? Randomized, single-blind, sham-controlled study on 96 patients: fast pain relief","volume":"99","author":"Pavone","year":"2017","journal-title":"Urol Int"},{"issue":"11","key":"2025080406264453100_ref70","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jsxm.2017.08.015","article-title":"Treatment of Peyronie\u2019s disease with collagenase clostridium histolyticum and vacuum therapy: a randomized, open-label pilot study","volume":"14","author":"Ralph","year":"2017","journal-title":"J Sex Med"},{"issue":"4","key":"2025080406264453100_ref71","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1111\/bju.14410","article-title":"Predictors of treatment success after collagenase clostridium histolyticum injection for Peyronie\u2019s disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study","volume":"122","author":"Cocci","year":"2018","journal-title":"BJU Int"},{"issue":"10","key":"2025080406264453100_ref72","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/j.jsxm.2018.08.012","article-title":"Sildenafil 25 mg ODT + collagenase Clostridium hystoliticum vs collagenase clostridium hystoliticum alone for the Management of Peyronie\u2019s disease: a matched-pair comparison analysis","volume":"15","author":"Cocci","year":"2018","journal-title":"J Sex Med"},{"issue":"5","key":"2025080406264453100_ref73","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.15171\/jlms.2019.S7","article-title":"Laser therapy for Peyronie\u2019s disease: a randomized control double-blind pilot study","volume":"10","author":"Allameh","year":"2019","journal-title":"J Lasers Med Sci"},{"issue":"4","key":"2025080406264453100_ref74","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41443-018-0027-5","article-title":"Patient perspectives on Peyronie\u2019s disease: results of poststudy interviews from a phase 2 trial of collagenase clostridium histolyticum","volume":"31","author":"Kaminetsky","year":"2019","journal-title":"Int J Impot Res"},{"issue":"4","key":"2025080406264453100_ref75","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1111\/bju.14602","article-title":"Penile traction therapy with the new device \u2018Penimaster PRO\u2019 is effective and safe in the stable phase of Peyronie\u2019s disease: a controlled multicentre study","volume":"123","author":"Moncada","year":"2019","journal-title":"BJU Int"},{"issue":"3","key":"2025080406264453100_ref76","doi-asserted-by":"publisher","first-page":"526","DOI":"10.5534\/wjmh.200048","article-title":"Oral administration and Intralesional injection of hyaluronic acid versus Intralesional injection alone in Peyronie\u2019s disease: results from a phase III study","volume":"39","author":"Cai","year":"2021","journal-title":"World J Mens Health"},{"issue":"9","key":"2025080406264453100_ref77","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.jsxm.2020.05.009","article-title":"A novel penile splint as early traction therapy after grafting techniques for Peyronie\u2019s disease","volume":"17","author":"Fern\u00e1ndez-Pascual","year":"2020","journal-title":"J Sex Med"},{"key":"2025080406264453100_ref78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.urology.2020.08.045","article-title":"Long-term curvature deformity characterization in men previously treated with collagenase clostridium Histolyticum for Peyronie\u2019s disease","volume":"146","author":"Goldstein","year":"2020","journal-title":"Subgrouped by Penile Plaque Calcification Urology"},{"issue":"12","key":"2025080406264453100_ref79","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.jsxm.2020.10.003","article-title":"Outcomes of RestoreX penile traction therapy in men with Peyronie\u2019s disease: results from open label and follow-up phases","volume":"17","author":"Joseph","year":"2020","journal-title":"J Sex Med"},{"key":"2025080406264453100_ref80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.51847\/debpd3Y","article-title":"New Therapeutical procedures of Peyronie\u2019s disease: transfer capacitive resistive energy in association with Hydroelectrophoresis with verapamil","volume":"9","author":"Maretti","year":"2020","journal-title":"Int J Pharm Res Allied Sci"},{"key":"2025080406264453100_ref81","doi-asserted-by":"publisher","first-page":"715","DOI":"10.2147\/RRU.S325929","article-title":"A randomized, single-blinded clinical trial evaluating the effect of extracorporeal shockwave treatment (ESWT) as add-on therapy to vacuum erectile device on Peyronie\u2019s disease","volume":"13","author":"Mortensen","year":"2021","journal-title":"Res Rep Urol"},{"key":"2025080406264453100_ref82","doi-asserted-by":"crossref","first-page":"e13754","DOI":"10.1111\/ijcp.13754","article-title":"Intralesional low-dose methylprednisolone for the treatment of active phase Peyronie\u2019s disease: a single-Centre, preliminary prospective non-randomised study","volume":"75","author":"Ure","year":"2021","journal-title":"Int J Clin Pract"},{"issue":"5","key":"2025080406264453100_ref83","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4111\/icu.20220145","article-title":"Intralesional collagenase clostridium histolyticum vs. verapamil injections in males with Peyronie\u2019s disease: a prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates","volume":"63","author":"Chung","year":"2022","journal-title":"Investig Clin Urol"},{"issue":"5","key":"2025080406264453100_ref84","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41443-021-00447-2","article-title":"Low-intensity shockwave therapy in Peyronie\u2019s disease: long-term results from a prospective, randomized, sham-controlled trial","volume":"34","author":"Sokolakis","year":"2022","journal-title":"Int J Impot Res"},{"issue":"5","key":"2025080406264453100_ref85","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1097\/JU.0000000000003634","article-title":"Comparison of collagenase clostridium histolyticum to surgery for the Management of Peyronie\u2019s disease: a randomized trial","volume":"210","author":"Green","year":"2023","journal-title":"J Urol"},{"issue":"4","key":"2025080406264453100_ref86","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/20905998.2024.2333583","article-title":"Intralesional injection of hyaluronic acid compared with verapamil in acute phase of Peyronie\u2019s disease: a prospective randomized clinical trial. Arab","volume":"22","author":"Abdel Fattah","year":"2024","journal-title":"J Urol"},{"issue":"8","key":"2025080406264453100_ref87","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/s41443-024-00844-3","article-title":"A phase 2 randomized, placebo-controlled crossover trial to evaluate safety and efficacy of platelet-rich plasma injections for Peyronie\u2019s disease: clinical trial update","volume":"36","author":"Ledesma","year":"2024","journal-title":"Int J Impot Res"},{"key":"2025080406264453100_ref88","first-page":"226","article-title":"A hospital based prospective comparative assessment of the efficacy of oral verapamil versus Intralesional verapamil injection in patients of Peyronie\u2019s disease","volume-title":"Int J Toxicol Pharmacol Res [Internet]","author":"Singh"},{"issue":"13","key":"2025080406264453100_ref89","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/1471-0528.15199","article-title":"Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials","volume":"125","author":"Hariton","year":"2018","journal-title":"BJOG"},{"key":"2025080406264453100_ref90","volume-title":"D-M. S.1 - 103rd Congress (1993-1994): National Institutes of Health Revitalization Act of 1993","author":"Sen. Kennedy"},{"key":"2025080406264453100_ref91","volume-title":"Enhancing the Diversity of Clinical Trial Populations: Eligibility Criteria, Enrollment Practices, and Trial Designs - Digital Collections - National Library of Medicine"},{"issue":"11","key":"2025080406264453100_ref92","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.33205","article-title":"Racial and ethnic disparities among participants in precision oncology clinical studies","volume":"4","author":"Aldrighetti","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2025080406264453100_ref93","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1001\/jamaoncol.2022.5511","article-title":"Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials: a meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"2025080406264453100_ref94","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.sxmr.2015.10.002","article-title":"The genetic basis of Peyronie disease: a review","volume":"4","author":"Herati","year":"2016","journal-title":"Sex Med Rev"},{"issue":"2","key":"2025080406264453100_ref95","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/archinte.164.2.165","article-title":"A twin study of erectile dysfunction","volume":"164","author":"Fischer","year":"2004","journal-title":"Arch Intern Med"},{"issue":"3","key":"2025080406264453100_ref96","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.euf.2019.08.006","article-title":"Erectile dysfunction and Peyronie\u2019s disease: genetic diseases?","volume":"6","author":"Patel","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"7","key":"2025080406264453100_ref97","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/andr.13223","article-title":"Significant familial clustering of Peyronie\u2019s disease in close and distant relatives","volume":"10","author":"Allen-Brady","year":"2022","journal-title":"Andrology"},{"issue":"4","key":"2025080406264453100_ref98","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/sj.ijir.3900857","article-title":"The international index of erectile function (IIEF): a state-of-the-science review","volume":"14","author":"Rosen","year":"2002","journal-title":"Int J Impot Res"},{"issue":"2","key":"2025080406264453100_ref99","first-page":"56","article-title":"African Americans and their distrust of the health care system: healthcare for diverse populations","volume":"14","author":"Kennedy","year":"2007","journal-title":"J Cult Divers"},{"issue":"5","key":"2025080406264453100_ref100","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.outlook.2004.04.012","article-title":"Community-based research: barriers to recruitment of African Americans","volume":"52","author":"Dancy","year":"2004","journal-title":"Nurs Outlook"},{"issue":"2","key":"2025080406264453100_ref101","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.esxm.2019.11.002","article-title":"Prevalence, risk factors, and erectile dysfunction associated with Peyronie\u2019s disease among men seeking urological care","volume":"8","author":"Segundo","year":"2020","journal-title":"Sex Med"},{"issue":"6","key":"2025080406264453100_ref102","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0027-9684(15)30361-8","article-title":"Recruiting intergenerational African American males for biomedical research studies: a major research challenge","volume":"103","author":"Byrd","year":"2011","journal-title":"J Natl Med Assoc"},{"issue":"4_Part_1","key":"2025080406264453100_ref103","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/j.1743-6109.2009.01584.x","article-title":"A cross-sectional study for the analysis of clinical, sexual and laboratory conditions associated to Peyronie\u2019s disease","volume":"7","author":"Rhoden","year":"2010","journal-title":"J Sex Med"},{"issue":"(19)","key":"2025080406264453100_ref104","first-page":"61","article-title":"Impact of race and ethnicity on clinical outcomes of collagenase clostridium histolyticum in patients with Peyronie\u2019s disease across Kaiser Permanente Southern California database","volume":"29","author":"Okene","journal-title":"Perm J"},{"issue":"19","key":"2025080406264453100_ref105","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1200\/JCO.22.00754","article-title":"Increasing racial and ethnic diversity in cancer clinical trials: an American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement","volume":"40","author":"Oyer","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/8\/1455\/63523531\/qdaf134.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/22\/8\/1455\/63523531\/qdaf134.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T10:26:50Z","timestamp":1754303210000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/22\/8\/1455\/8168848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":105,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,6,18]]},"published-print":{"date-parts":[[2025,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdaf134","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,6,18]]}}}